countri
larger
drugresist
tuberculosi
patient
cohort
requir
consider
concert
effort
includ
quicker
diagnosi
increas
treatment
coverag
better
surveil
data
notabl
limit
data
avail
assess
tempor
trend
drugresist
tuberculosi
high
tuberculosi
burden
countri
concomit
high
hiv
preval
south
africa
estim
tuberculosi
incid
declin
annual
like
driven
increas
coverag
antiretrovir
treatment
hiv
contrast
drugresist
tuberculosi
proport
tuberculosi
increas
two
nation
survey
primarili
driven
increas
rifampicin
monoresist
tuberculosi
systemat
review
suggest
associ
hiv
drugresist
tuberculosi
increas
risk
drugresist
tuberculosi
individu
tuberculosi
treatment
naiv
suggest
stronger
associ
transmit
resist
acquir
howev
hiv
infect
also
associ
increas
drugresist
acquisit
tuberculosi
treatment
taken
togeth
data
suggest
associ
hiv
drugresist
tuberculosi
depend
epidemiolog
set
highlight
necess
improv
tuberculosi
drugresist
surveil
set
high
hiv
preval
recommend
treatment
drugresist
tuberculosi
requir
lengthi
cours
often
toxic
ineffect
drug
treatment
success
approxim
howev
past
year
new
repurpos
drug
becom
avail
allow
shorter
allor
effect
drugresist
tuberculosi
treatment
regimen
regimen
combin
rapid
diagnost
offer
potenti
improv
treatment
access
even
resourceconstrain
set
howev
scaleup
requir
substanti
commit
part
govern
highburden
countri
global
funder
avert
situat
drugresist
tuberculosi
becom
new
normal
declar
compet
interest
upsurg
number
mer
case
seen
saudi
arabia
oman
case
report
juli
june
compar
case
januari
march
worryingli
although
merscov
continu
circul
middl
east
progress
advanc
prioriti
research
develop
epidemiolog
rapid
diagnost
treatment
vaccin
includ
region
one
health
activ
slow
importantli
despit
mani
mer
expert
group
stakehold
meet
defin
prioriti
research
need
major
knowledg
gap
remain
epidemiolog
transmiss
pathogenesi
phylogenet
evolut
merscov
major
opportun
appropri
longitudin
crosssect
studi
fill
gap
recurr
commun
nosocomi
outbreak
mer
saudi
arabia
miss
contrast
sever
studi
done
mer
outbreak
south
korea
yield
import
epidemiolog
clinic
virolog
manag
outcom
data
merscov
sequenc
variant
detect
south
korean
outbreak
mutat
incorpor
circul
viru
remark
extens
studi
mutat
occur
surfac
glycoprotein
predict
surfac
glycoprotein
crucial
viru
entri
sever
acut
respiratori
syndrom
epidem
evolv
bind
tightli
cellular
receptor
contrast
chang
detect
merscovsurfac
glycoprotein
appear
decreas
bind
expect
decreas
virul
transmiss
howev
chang
could
benefici
merscov
facilit
evas
antibodi
respons
merscov
transmiss
occur
commun
household
set
healthcar
facil
nosocomi
outbreak
major
featur
decreas
due
increas
awar
implement
infect
control
measur
although
zoonot
transmiss
camel
thought
primari
mode
transmiss
substanti
proport
patient
describ
camel
contact
merscov
infect
camel
throughout
africa
common
although
convinc
serolog
virolog
evid
exist
human
merscov
infect
africa
key
question
human
merscov
infect
begin
middl
east
africa
patient
without
contact
camel
acquir
diseas
sequenc
analysi
merscov
isol
patient
middl
east
reveal
mutat
viru
transient
revers
wild
type
sequenc
inconsist
continu
adapt
human
mani
viru
variant
observ
circul
camel
time
suggest
continu
cameltohuman
transmiss
might
obscur
adapt
chang
human
viru
small
differ
sequenc
observ
east
african
saudi
arabian
merscov
isol
compar
substanti
differ
observ
compar
west
african
merscov
includ
delet
detect
west
african
merscov
differ
might
contribut
diminish
transmiss
howev
anoth
possibl
differ
might
occur
humancamel
contact
africa
versu
middl
east
camel
worker
owner
close
contact
camel
thu
increas
preval
merscov
immunoposit
gener
popul
camel
worker
mild
subclin
diseas
might
transmit
merscov
either
directli
indirectli
suscept
individu
eg
comorbid
would
present
sporad
case
studi
point
sever
direct
prioriti
research
intervent
decreas
persist
threat
merscov
transmiss
first
continu
sequenc
analysi
merscov
endem
countri
need
establish
viral
evolut
case
south
korean
outbreak
second
increas
understand
camelhuman
interact
pattern
camel
graze
africa
middl
east
could
provid
insight
transmiss
differ
third
effect
vaccin
human
best
way
prevent
spread
mer
logist
issu
small
number
sporad
mer
case
differ
geograph
locat
need
overcom
altern
vaccin
juvenil
camel
might
block
transmiss
fourth
develop
antivir
therapi
merscov
would
improv
patient
outcom
decreas
viru
burden
could
decreas
transmiss
final
continu
effort
educ
camel
worker
infect
control
measur
handwash
wear
protect
gear
handl
camel
especi
juvenil
one
upper
respiratori
tract
infect
crucial
minimis
transmiss
persist
merscov
transmiss
middl
east
year
first
discov
mani
unansw
question
regard
mer
rais
recurr
mer
expert
group
annual
meet
requir
major
chang
current
statu
quo
prevent
merscov
evolv
next
global
pandem
seriou
financi
polit
commit
especi
mersendem
countri
need
establish
take
forward
effect
multidisciplinari
one
health
consortia
establish
effect
multidisciplinari
research
collabor
